1Uchikoba T,Horiuchi K,Oka F,et al.Diagnosing the location of carcinoma in situ (CIS) of the urinary bladder using pirarubicin hydrochloride.Urol Int,2005,74:235-239.
2Agrawal MS,Agrawal M,Bansal S,et al.The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma.Urology,2007,70:1075-1078.
3Birkhahn M,Mitra AP,Williams AJ,et al.Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles.Eur Urol,2010,57:12-20.
4Millan-Rodriquez F,Chechile-Tomiolo G,Salvador-Bayarri J,et al.Multivariate analysis of the prognostic factors of primary superficial bladder cancer.J Urol,2000,163:73-78.
5Sylvester RJ,van der Meijden A,Witjes JA,et al.High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.Urology,2005,66(6 Suppl 1):90-107.
6Koenig F,McGovern FJ,Larne R,et al.Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid.BJU Int,1999,83:129-135.
7Witjes JA,Douglass J.The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer.Nat Clin Pract Urol,2007,4:542-549.
9Gillenwater JY,Wein AJ. Summary of the national institute of arthritis,digestive and kidney diseases workshop on interstitial cystitis,National Institutes of Health,Bethesda,Maryland,August 28-29[J].The Journal of Urology,1988.203-206.
10O'Leary MP,Sant GR,Fowler FJ Jr. The interstitial cystitis symptom index and problem index[J].Urology,1997.58-63.
